An Antimicrobial Stewardship Program with a Focus on Reducing Fluoroquinolone Overuse

被引:35
作者
Wong-Beringer, Annie [1 ,2 ]
Nguyen, Lee H. [4 ]
Lee, Michelle [5 ]
Shriner, Kimberly A. [3 ]
Pallares, Jean [2 ]
机构
[1] Univ So Calif, Sch Pharm, Los Angeles, CA 90033 USA
[2] Huntington Hosp, Dept Pharm Serv, Pasadena, CA USA
[3] Huntington Hosp, Dept Internal Med, Pasadena, CA USA
[4] Loma Linda Univ, Sch Pharm, Loma Linda, CA 92350 USA
[5] Arcadia Methodist Hosp, Dept Pharm, Arcadia, CA USA
来源
PHARMACOTHERAPY | 2009年 / 29卷 / 06期
关键词
stewardship; fluoroquinolones; antimicrobial overuse; infectious diseases pharmacist; PSEUDOMONAS-AERUGINOSA; CLOSTRIDIUM-DIFFICILE; UNITED-STATES; RISK-FACTORS; LEVOFLOXACIN; RESISTANCE; PNEUMONIA; CIPROFLOXACIN; PREVALENCE; FAILURE;
D O I
10.1592/phco.29.6.736
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The fluoroquinolones have become the leading class of antimicrobial agents prescribed to adults in the United States. Resistance of key pathogens to fluoroquinolones has developed rapidly in parallel with increased prescribing of these drugs. We describe our pharmacist-led antimicrobial stewardship program that focused on reducing inappropriate prescribing Of fluoroquinolones, with the goals of limiting the development of resistance and improving patient Outcomes. Core strategies were regular monitoring and reporting of resistance trends observed on institutional antibiograms, performing drug audits and related studies with intervention and feedback to prescribers, implementing an automatic parenteral-to-oral conversion program, establishing and implementing a P-lactam-based institutional guideline for empiric therapy, and educating prescribers. This successful program reduced empiric prescribing of fluoroquinolones by 30%, improved Susceptibility for all antipseudomonal agents against Pseudomonas aeruginosa overall by 10%, and decreased mortality associated with P. aeruginosa infections by 2-fold. Our stewardship program clearly demonstrated that pharmacists can take on leadership roles to positively change antimicrobial prescribing at the institutional level and improve patient outcomes.
引用
收藏
页码:736 / 743
页数:8
相关论文
共 36 条
  • [1] The effect of formulary restriction in the use of antibiotics in an Italian hospital
    Bassetti, M
    Di Biagio, A
    Rebesco, B
    Amalfitano, ME
    Topal, J
    Bassetti, D
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (6-7) : 529 - 534
  • [2] Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia
    Chang, NN
    Murray, CK
    Houck, PM
    Bratzler, DW
    Greenway, C
    Guglielmo, BJ
    [J]. PHARMACOTHERAPY, 2005, 25 (01): : 59 - 66
  • [3] Hospital-wide restriction of clindamycin:: Effect on the incidence of Clostridium difficile-associated diarrhea and cost
    Climo, MW
    Israel, DS
    Wong, ES
    Williams, D
    Coudron, P
    Markowitz, SM
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (12) : 989 - +
  • [4] Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Davidson, R
    Cavalcanti, R
    Brunton, JL
    Bast, DJ
    de Azavedo, JCS
    Kibsey, P
    Fleming, C
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) : 747 - 750
  • [5] Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC Mutation
    de Cueto, A.
    Rodriguez, J. M.
    Soriano, M. J.
    Lopez-Cerero, L.
    Venero, J.
    Pascual, A.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (04) : 1558 - 1560
  • [6] Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    Dellit, Timothy H.
    Owens, Robert C.
    McGowan, John E., Jr.
    Gerding, Dale N.
    Weinstein, Robert A.
    Burke, John P.
    Huskins, W. Charles
    Paterson, David L.
    Fishman, Neil O.
    Carpenter, Christopher F.
    Brennan, P. J.
    Billeter, Marianne
    Hooton, Thomas M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (02) : 159 - 177
  • [7] Antimicrobial resistance trends and outbreak frequency in United States hospitals
    Diekema, DJ
    BootsMiller, BJ
    Vaughn, TE
    Woolson, RF
    Yankey, JW
    Ernst, EJ
    Flach, SD
    Ward, MM
    Franciscus, CLJ
    Pfaller, MA
    Doebbeling, BN
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (01) : 78 - 85
  • [8] Empey PE, 2001, ANN PHARMACOTHER, V35, P687
  • [9] Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
    Endimiani, A
    Brigante, G
    Bettaccini, AA
    Luzzaro, F
    Grossi, P
    Toniolo, AQ
    [J]. BMC INFECTIOUS DISEASES, 2005, 5 (1)
  • [10] A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
    File, TM
    Segreti, J
    Dunbar, L
    Player, R
    Kohler, R
    Williams, RR
    Kojak, C
    Rubin, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 1965 - 1972